Technical Analysis for MTEM - Molecular Templates, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 2.07 | -24.73% | -0.68 |
MTEM closed down 24.73 percent on Monday, March 18, 2024, on 6.94 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 28
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
Expansion Breakdown | Bearish Swing Setup | 0.00% | |
Volume Surge | Other | 0.00% | |
Wide Range Bar | Range Expansion | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% |
Alert | Time |
---|---|
Down 2 ATRs | about 9 hours ago |
60 Minute Opening Range Breakdown | about 13 hours ago |
2x Volume Pace | about 14 hours ago |
1.5x Volume Pace | about 14 hours ago |
3x Volume Pace | about 14 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/28/2024
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Treatment Of Cancer Cancer Treatment Oncology Chemical Elements Lymphoma Oxygen Toxins Prodrugs Evofosfamide Prodrug Nitrogen Mustards
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Treatment Of Cancer Cancer Treatment Oncology Chemical Elements Lymphoma Oxygen Toxins Prodrugs Evofosfamide Prodrug Nitrogen Mustards
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 9.45 |
52 Week Low | 2.0 |
Average Volume | 10,362 |
200-Day Moving Average | 5.87 |
50-Day Moving Average | 3.57 |
20-Day Moving Average | 3.49 |
10-Day Moving Average | 3.06 |
Average True Range | 0.33 |
RSI (14) | 20.63 |
ADX | 32.72 |
+DI | 7.64 |
-DI | 41.10 |
Chandelier Exit (Long, 3 ATRs) | 3.12 |
Chandelier Exit (Short, 3 ATRs) | 3.00 |
Upper Bollinger Bands | 4.61 |
Lower Bollinger Band | 2.37 |
Percent B (%b) | -0.14 |
BandWidth | 64.05 |
MACD Line | -0.32 |
MACD Signal Line | -0.16 |
MACD Histogram | -0.1537 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.21 | ||||
Resistance 3 (R3) | 3.31 | 3.04 | 3.02 | ||
Resistance 2 (R2) | 3.04 | 2.75 | 2.99 | 2.96 | |
Resistance 1 (R1) | 2.55 | 2.57 | 2.42 | 2.45 | 2.89 |
Pivot Point | 2.28 | 2.28 | 2.21 | 2.23 | 2.28 |
Support 1 (S1) | 1.79 | 1.99 | 1.66 | 1.69 | 1.25 |
Support 2 (S2) | 1.52 | 1.81 | 1.47 | 1.18 | |
Support 3 (S3) | 1.03 | 1.52 | 1.12 | ||
Support 4 (S4) | 0.93 |